Table 5.

Multivariate Model of Type 2 Diabetes Mellitus Incidence (Defined by Incident Antihyperglycemic Medication Prescription at 18 Months Postinitiation) by Integrase Strand Transfer Inhibitor Versus Nonintegrase Strand Transfer Inhibitor

Factor	HR	Standard error	95% CI	p
InSTI use (vs. non-InSTI)	1.30	0.76	−0.19 to 2.80	0.73
ART initiation year 2010–2012	0.77	0.93	−1.04 to 2.59	0.78
ART initiation year 2012–2014	1.44	0.79	−0.11 to 2.98	0.65
ART initiation year 2014–2016	1.25	0.97	−0.65 to 3.15	0.82
ART initiation year 2016–2018	2.66	1.14	0.43 to 4.88	0.39
Age at ART initiation	1.03	0.02	0.99 to 1.07	0.19
Sex: female	2.72	0.54	1.66 to 3.78	0.06
Race: white	0.58	0.78	−0.96 to 2.11	0.48
Ethnicity: Hispanic or Latinx	1.42	0.62	0.21 to 2.63	0.57
NRTI backbone: TAF	1.60	1.03	−0.42 to 3.62	0.65
NRTI backbone: ABC	2.67	0.72	1.26 to 4.08	0.17
NRTI backbone: other	0.00	4,795.79	−9,399.73 to 9,399.74	1.00
CD4 at ART initiation	1.00	0.01	1.00 to 1.00	0.20
HIV-1 RNA viral load at ART initiation	1.00	0.00	1.00 to 1.00	0.456

ABC, abacavir; TAF, tenofovir alafenamide.